journal article·2020-01-01Open access

CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway

Qinghua Yu, Yujie Lei, Yunchao Huang, Jiguang Zhang, Yangming Chen, Kai Chen, Jianbin Lin, Shihui Sun, Xing Lin

Abstract

Our previous study found that IL33 repressed the growth of pulmonary adenocarcinoma (PA) via regulation of dendritic cells (DCs). However, the molecular mechanism of DCs in PA is still unclear. The present work showed that CYLD−/− mice have a shorter survival rate of PA, and knockout CYLD in DCs also repress the progression of PA in mice. Subsequently, we found that decreased expression and reduced the nuclear translocation of NF-κB signalling was observed in CYLD knockout DCs, and inhibiting NF-κB pathway repressed DCs-induced proliferation and function of CD4+ T cells. These results indicated that CYLD function as a tumour suppresser in PA via regulates the function of DCs through NF-κB signalling pathway. Our findings support that CYLD serves as a potential target for immunotherapy in PA.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Cancer-related molecular mechanisms research · NF-κB Signaling Pathways

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University

Department of Thoracic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University

Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University

References (33)

Show source-provided references
1. 10.1158/2326-6066.CIR-17-065510.1158/2326-6066.CIR-17-0655 ↗
2. 10.1038/ncomms160910.1038/ncomms1609 ↗
3. 10.1158/0008-5472.CAN-17-130710.1158/0008-5472.CAN-17-1307 ↗
4. 10.1038/srep4539510.1038/srep45395 ↗
5. 10.1158/1078-0432.CCR-16-282110.1158/1078-0432.CCR-16-2821 ↗
6. 10.1186/s13046-015-0126-910.1186/s13046-015-0126-9 ↗
7. 10.1016/j.jep.2019.11198010.1016/j.jep.2019.111980 ↗
8. 10.1039/C9NR03510A10.1039/C9NR03510A ↗
9. 10.1080/21691401.2019.159692610.1080/21691401.2019.1596926 ↗
10. 10.1038/cddis.2011.8210.1038/cddis.2011.82 ↗
11. 10.7150/thno.1084410.7150/thno.10844 ↗
12. 10.1038/leu.2011.35710.1038/leu.2011.357 ↗
13. 10.1093/carcin/bgl08110.1093/carcin/bgl081 ↗
14. 10.1093/carcin/bgt33510.1093/carcin/bgt335 ↗
15. 10.1016/j.immuni.2007.07.01110.1016/j.immuni.2007.07.011 ↗
16. Zhang LM, Zhou JJ, Luo CL. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-kappaB activation. Arthritis Res Ther. 2018;20(1):219.
17. 10.1053/j.gastro.2018.10.02310.1053/j.gastro.2018.10.023 ↗
18. 10.3389/fimmu.2015.0065010.3389/fimmu.2015.00650 ↗
19. 10.1016/j.celrep.2016.05.03210.1016/j.celrep.2016.05.032 ↗
20. 10.1182/blood-2008-08-17548910.1182/blood-2008-08-175489 ↗
21. 10.1038/s41419-018-0889-y10.1038/s41419-018-0889-y ↗
22. 10.1038/cdd.2009.4310.1038/cdd.2009.43 ↗
23. 10.1038/leu.2017.16810.1038/leu.2017.168 ↗
24. 10.1158/2326-6066.CIR-17-011710.1158/2326-6066.CIR-17-0117 ↗
25. 10.1080/2162402X.2018.143108410.1080/2162402X.2018.1431084 ↗
26. 10.1016/j.jtho.2017.10.02010.1016/j.jtho.2017.10.020 ↗
27. 10.1007/s00005-011-0157-710.1007/s00005-011-0157-7 ↗
28. 10.1016/j.yexcr.2019.11149710.1016/j.yexcr.2019.111497 ↗
29. 10.1371/journal.ppat.100743510.1371/journal.ppat.1007435 ↗
30. 10.1016/j.cell.2006.03.04110.1016/j.cell.2006.03.041 ↗
31. Li Y, Huang W, Xu Y, et al. CYLD deubiquitinase negatively regulates high glucose-induced NF-kappaB inflammatory signaling in mesangial cells. BioMed Res Int. 2017;2017:1.10.1155/2017/3982906 ↗
32. 10.3389/fnmol.2017.0036310.3389/fnmol.2017.00363 ↗
33. 10.4049/jimmunol.120199310.4049/jimmunol.1201993 ↗